Absci Corporation to Participate in Annual Healthcare Conference
Absci Corporation (Nasdaq: ABSI), a pioneering data-first generative AI drug creation company, is excited to announce its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. This major event will take place in San Francisco, drawing attention from industry experts and investors alike.
Event Details and Presentation Schedule
The management team at Absci is scheduled to present on Wednesday at 4:30 p.m. Pacific Time, which corresponds to 7:30 p.m. Eastern Time. This presentation will offer valuable insights into the company’s innovative approaches and advancements in drug development.
Accessing the Presentation
Individuals interested in following the company's presentation can access a live stream, as well as an archived version, on Absci’s investor relations website. This provides a great opportunity for stakeholders to catch up on Absci's latest developments and future plans.
Understanding Absci’s Mission and Technology
At the core of Absci’s mission is the commitment to integrate artificial intelligence with state-of-the-art wet lab technologies. This combination allows the company to develop biologics more efficiently and effectively, ensuring that patients receive better treatments in a shorter time frame. The innovative Integrated Drug Creation™ platform is designed to enhance drug success rates by optimizing several characteristics simultaneously, thereby accelerating the path from concept to clinic.
Rapid Development and Screening Capabilities
Absci’s cutting-edge technology enables them to screen billions of cells each week, making it possible to transition from AI-designed candidates to validated candidates within a mere six weeks. This speedy process is crucial in the fast-paced pharmaceutical landscape, where time-to-market can significantly influence a drug's success.
Global Presence of Absci
Absci operates globally, with its headquarters located in Vancouver, Washington, and an AI Research Lab situated in New York City. Furthermore, the company boasts an Innovation Center in Zug, Switzerland, thus enhancing its ability to tap into global talent and technological advancements in biotech.
Continuous Growth and Expansion
As Absci continues to make significant strides in drug discovery and development, the company remains focused on refining its technology and expanding its services. This commitment to innovation positions Absci as a leader in the biopharma industry, making lasting impacts on the market.
Investor and Media Relations
For inquiries regarding the company’s progress and future directions, interested parties are encouraged to reach out to Absci's investor relations contact:
Investor Contact
Alex Khan
VP, Finance & Investor Relations
Email: investors@absci.com
For media requests, please contact:
Media Contact
Email: press@absci.com
Frequently Asked Questions
What is Absci Corporation known for?
Absci Corporation is known for its innovative approach to drug development using generative AI combined with advanced wet lab technologies.
When will Absci present at the J.P. Morgan Healthcare Conference?
Absci will present on Wednesday at 4:30 p.m. Pacific Time during the conference.
How can I access Absci's conference presentation?
The presentation can be accessed live and archived on the company’s investor relations website.
Where is Absci located?
Absci's headquarters is in Vancouver, Washington, with additional locations in New York City and Zug, Switzerland.
Who can I contact for investor or media inquiries about Absci?
For investor inquiries, contact Alex Khan at investors@absci.com; for media inquiries, reach out via press@absci.com.
